EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma

Macarena I de la Fuente iD, Mehdi Touat iD, Martin J van den Bent, Matthias Preusser, Katherine B Peters iD, Robert J Young, Raymond Y Huang, Benjamin M Ellingson, David Capper iD, Joanna J Phillips, Lia M Halasz, Helen A Shih und 14 weitere

Neuro-Oncology · 21.06.2025 · 27 (5) · 1135-1148

DOI: 10.1093/neuonc/noae259 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 25.12.2024. Verfasst von Macarena I de la Fuente und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Miami, Miami, Florida, USA. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Glioma, Brain Neoplasms, Mutation. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Dowskin Family Foundation, Sylvester Comprehensive Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isocitrate dehydrogenase (IDH)-mutant gliomas are the most common malignant primary brain tumors in young adults. This condition imposes a substantial burden on patients and their caregivers, marked by neurocognitive deficits and high mortality rates due to tumor progression, coupled with significant morbidity from current treatment modalities. Although surgery, radiation therapy, and chemotherapy improve survival, these treatments can adversely affect cognitive function, quality of life, finances, employment status, and overall independence. Consequently, there is an urgent need for innovative strategies that delay progression and the use of radiation therapy and chemotherapy. The recent Federal Drug Administration (FDA) approval of vorasidenib, a brain-penetrant small molecule targeting mutant IDH1/2 proteins, heralds a shift in the therapeutic landscape for IDH-mutant gliomas. In this review, we address the role of vorasidenib in the treatment of IDH-mutant gliomas, providing a roadmap for its incorporation into daily practice. We discuss ongoing clinical trials with vorasidenib and other IDH inhibitors, as single-agent or in combination with other therapies, as well as current challenges and future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseGliomaBrain NeoplasmsMutationTriazinesAntineoplastic AgentsPyrimidinesHumans

Stichwörter der Autor:innen

1p-19q co-deleted oligodendroglioma | glioma | IDH-mutant astrocytoma | IDH-mut…

Substanzen

Isocitrate DehydrogenaseTriazinesAntineoplastic AgentsPyrimidines

Autor:innen und Institutionen

  • Department of Neurology, University of Miami, Miami, Florida, USA.
  • Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
  • Service de Neuro-oncologie, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, Paris Brain Institute, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.
  • Department of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Department of Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA.

ORCID-Profile: Macarena I de la Fuente, Mehdi Touat, Katherine B Peters, David Capper, Michael Weller, Yoshiki Arakawa, David A Reardon, Shawn Hervey-Jumper

Förderung

  • NCI NIH HHS
  • Dowskin Family Foundation
  • Sylvester Comprehensive Cancer Center

Zitieren

APA

de la Fuente, M. I., Touat, M., van den Bent, M. J., Preusser, M., Peters, K. B., Young, R. J., Huang, R. Y., Ellingson, B. M., Capper, D., Phillips, J. J., Halasz, L. M., Shih, H. A., Rudà, R., Lim-Fat, M. J., Blumenthal, D. T., Weller, M., Arakawa, Y., Whittle, J. R., Ducray, F., …, & Wen, P. Y. (2025). The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. Neuro-Oncology, 27(5), 1135-1148. https://doi.org/10.1093/neuonc/noae259

Vancouver

de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, et al. The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. Neuro-Oncology. 2025;27(5):1135-1148. doi:10.1093/neuonc/noae259

BibTeX
@article{delaFuente2025,
  author = {de la Fuente, Macarena I and Touat, Mehdi and van den Bent, Martin J and Preusser, Matthias and Peters, Katherine B and Young, Robert J and Huang, Raymond Y and Ellingson, Benjamin M and Capper, David and Phillips, Joanna J and Halasz, Lia M and Shih, Helen A and Rudà, Roberta and Lim-Fat, Mary Jane and Blumenthal, Deborah T and Weller, Michael and Arakawa, Yoshiki and Whittle, James R and Ducray, François and Reardon, David A and Bi, Wenya Linda and Minniti, Giuseppe and Rahman, Rifaquat and Hervey-Jumper, Shawn and Chang, Susan M and Wen, Patrick Y},
  title = {The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {5},
  pages = {1135--1148},
  doi = {10.1093/neuonc/noae259}
}
Kostenlos starten →